This quarterly edition of the St. Baldrick’s Foundation Research Outcomes features work focused on fighting neuroblastoma, rhabdomyosarcoma, and acute lymphoblastic leukemia as well as research to improve identification of survivors at risk for cardiotoxicity.
Thank you for making these outcomes – and more – possible.
Your generosity makes a difference for kids with cancer. This edition of the St. Baldrick’s Foundation Research Outcomes recognizes research that is making treatments less toxic, evaluating new drugs, and working to prevent late effects. Thank you for making research possible.
This was written by Hudson’s mom, Jessica McKearney.
I work as a Nurse Practitioner and Kyle works as a Project Manager. We live in a small town in Northeast Iowa. Before March 2019, Hudson was an energetic, Mickey Mouse and car loving toddler. He was spirited, happy, loved to dance and kept us on our toes. In November 2018, Hudson became a big brother to his sister Violet. Two under two was exciting and exhausting. Hudson was caring, empathetic, and always wanted to be with Violet. They had an incredible bond, and we were grateful to have two happy and healthy toddlers.
What is acute lymphoblastic leukemia?
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells that normally fight infection. The cells do not grow and develop properly, filling up the bone marrow inside bones, where blood is normally made.
ALL is the most common type of childhood cancer, accounting for 35% of all cancers in children. Each year, there are about 2,900 new cases of children and adolescents diagnosed with ALL in the United States alone.
Its signs and symptoms resemble other common illnesses, which often leads to other treatments before the leukemia diagnosis is made.
Back in April, Ambassador Zach was finally healthy enough after his bone marrow transplant to go out in public. What did he decide to do after that momentous milestone? He joined the hundreds of advocates speaking up for kids’ cancer research on Capitol Hill during Childhood Cancer Action Days. Here’s his recap of that trip and the big moments that have come since …
Ambassador Zach poses for a photo in front of the United States Capitol building and its famous dome during Childhood Cancer Action Days in April.
I received a bone marrow transplant over a year ago, and I was so glad that I was healthy enough to speak on Capitol Hill this past April as a St. Baldrick’s ambassador. As an ambassador, I am a face and a voice for childhood cancer, and while in Washington, D.C., my family and I represented thousands of children and families who are affected by childhood cancer. I was lucky enough to share my story and talk about the importance of funding childhood cancer research through the STAR (the Survivorship, Treatment, Access and Research) Act, the most comprehensive childhood cancer legislation ever taken up by Congress. With the recent passage of the STAR Act, we have come so far, but we still have so far to go.
Honored Kid Jack is selfless, brave, passionate, and funny. The seventh grader works hard, even when the odds are against him and if he could be friends with everyone in the world, he would be. In a word, Jack is special. Even cancer couldn’t take that away from him. And that’s what makes him a legendary hero to us — and this year’s League Champion of the St. Baldrick’s League of Legendary Heroes. You can be a legendary hero too! Get started today.
Jack was named 2018 League Champion for the League of Legendary Heroes because of his dedication to fundraising for kids’ cancer research. Photo by Courtney Van Alice Photography
Driving home from a visit with her sister, Vickie decided to run an errand. She pulled into the parking lot at Office Depot and stopped the car, expecting her son, Jack, to get out with her. But he didn’t.
“He’s like, ‘I can’t get out of the car, Mom. I can’t move,’ And I was like, ‘What? You were just wrestling with your cousin.’”
From its inaugural Phase 1 clinical trial through its successful Phase 2 trial, we have traced the path of Kymriah, a recent immunotherapy and gene therapy breakthrough for kids with high-risk leukemia and few options, like Honored Kids Austin and Ori. (Read the whole series here.) Now, with a historic decision made in August, we are at the end of our story, but not at the end of the story of Kymriah. Instead, Kymriah’s is just beginning – and starting a new chapter of hope for kids with cancer.
Austin (left) and Ori (right) are both alive today thanks to Kymriah and their participation in the Phase 1 and Phase 2 trials.
On August 30, 2017, big news rippled through the childhood cancer community. On that late summer day – before the start of Childhood Cancer Awareness Month – the FDA made a historic move that changed the landscape of childhood cancer research forever.
Over a series of four blogs — catch up with parts one and two about the Phase 1 trial — we are tracing the path of Kymriah, a recent immunotherapy and gene therapy breakthrough for kids with high-risk leukemia, like Honored Kid Ori.
After relapsing for the second time and with his cancer spreading to his nervous system, Ori’s best chance at life was a Phase 2 trial of this experimental CAR T cell therapy. With a sunny attitude and staggering strength of spirit, Ori gave this new treatment a shot – with astonishing results.
Ori was in cancer treatment for much of his young life and throughout the journey, his strength and positive attitude have been remarkable. “He has been through so much, but has done it all with a great attitude and a smile on his face,” said his mom, Kaye.
When a child with cancer relapses the first time, their treatment options shrink. But when a child with cancer relapses again, their options and chances at survival don’t just shrink – they’re nearly extinguished. That is what happened to Ori.
Investing in the next generation of childhood cancer researchers — like researcher and St. Baldrick’s International Scholar Dr. Joseph Lubega — can change the lives of kids with cancer all over the world. Read on (and watch a video shot at the Uganda Cancer Institute) to learn more about the huge impact Dr. Lubega is making on kids with cancer in East Africa.
When Belinda heard, ‘leukemia,’ she was terrified.
She feared cancer. Belinda saw the impact it had on her family. In fact, she’d attended her cousin’s funeral in the spring. But cancer striking her 5-year-old daughter, Christa? How could that happen?
We sat down virtually with St. Baldrick’s researcher, Stephan A. Grupp, MD, PhD, for a Q&A on immunotherapy. Dr. Grupp, located at Children’s Hospital of Philadelphia, is a key member of the Stand Up to Cancer – St. Baldrick’s Pediatric Dream Team*. He treated the first child with CAR T cell therapy, which was recently approved by the FDA for acute lymphoblastic leukemia (ALL). Check out our Twitter chat with Dr. Grupp and see what he thinks the future is for immunotherapy and childhood cancers.
Older Posts »